Core Viewpoint - The stock of Insilico Medicine (03696) has seen a significant increase, reaching a new high of HKD 61.30, with a current price of HKD 60.10, reflecting a 5.44% rise and a trading volume of HKD 61.32 million [1][4]. Group 1: Company Developments - Insilico Medicine has entered into a long-term R&D collaboration with Schwabe to develop anti-tumor drugs using its AI platform, Pharma.AI [1][4]. - The company has extensive experience in AI-driven tumor drug development and has established a pipeline covering various cancer indications [1][4]. - Two specific inhibitors, TEAD inhibitor ISM6331 and MAT2A inhibitor ISM3412, have initiated global multi-center Phase I clinical trials, with four additional tumor projects licensed out [1][4]. Group 2: Market Position and Financials - According to Zhongyou Securities, Insilico Medicine has a prestigious base of cornerstone investors and is a leader in the AI drug discovery field [1][4]. - The Pharma.AI platform has incubated over 20 assets in clinical or IND application stages, with three assets licensed to international pharmaceutical companies, totaling a contract value of up to USD 2.1 billion, alongside one asset in Phase II development [1][4].
英矽智能盘中涨超7%创新高 公司AI赋能肿瘤药物研发能力再获认可